Three changes could transform hemagglutinin of bird flu to bind more tightly to human receptors, a new study says.
The firm's Q4 global influenza sales were up 60 percent year over year, and in 2016 its global infectious disease business achieved double-digit sales growth.
Influenza revenues rose 112 percent due to an especially long and severe respiratory disease season, dominated by a virulent H3N2 strain of influenza.
While point-of-care molecular testing of patients with respiratory illness wasn't associated with lower antibiotic use, patients tested had shorter drug courses.
The Liat point of care system system has launched with four assays, including three respiratory tests and a novel test for Clostridium difficile.
Genetic analysis finds that the bird flu strain found on a Tennessee chicken farm differs from one linked to multiple deaths in China, Reuters reports.
In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
The White House Office of Science and Technology Policy has new guidelines for potential pandemic pathogen research, according to ScienceInsider.
The company said it expects revenues of $52 million to $53 million for the quarter, compared to analysts' average estimate of $63.1 million.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.